Prospect: information for the patient
BACEQ 25 mg prolonged-release injectable suspension EFG
BACEQ 50 mg prolonged-release injectable suspension EFG
BACEQ 75 mg prolonged-release injectable suspension EFG
BACEQ 100 mg prolonged-release injectable suspension EFG
BACEQ 150 mg prolonged-release injectable suspension EFG
Initial treatment pack:
BACEQ 150 mg and BACEQ 100 mg prolonged-release injectable suspension EFG
Read this prospect carefully before starting to use this medication, because
it contains important information for you.
1. What isBACEQand what it is used for
2. What you need to know before starting to useBACEQ
3. How to useBACEQ
4. Possible adverse effects
5. Storage ofBACEQ
6. Contents of the pack and additional information
BACEQ contains the active ingredient paliperidone, which belongs to the class of antipsychotic medications, and is used as maintenance treatment for the symptoms of schizophrenia in adult patients stabilized with paliperidone or risperidone.
If you have shown a response to paliperidone or risperidone in the past and have mild or moderate symptoms, your doctor may start treatment with BACEQ without prior stabilization with paliperidone or risperidone.
Schizophrenia is a disorder with "positive" and "negative" symptoms. Positive means an excess of symptoms that are normally not present. For example, a person with schizophrenia may hear voices or see things that do not exist (known as hallucinations), have false beliefs (known as delusions) or have an abnormal distrust of others. Negative refers to the lack of behaviors or feelings that are normally present. For example, a person with schizophrenia may withdraw into themselves and not respond to any emotional stimulus or may have difficulty speaking in a clear and logical way. People who suffer from this disorder may also feel depressed, anxious, guilty, or tense.
BACEQ may help alleviate the symptoms of your illness and prevent them from recurring.
No use paliperidonapaliperidone
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to use BACEQ.
This medicine has not been studied in elderly patients with dementia. However, elderly patients with dementia who are being treated with similar medicines may have an increased risk of stroke or death (see section 4, possible side effects).
All medicines have side effects and some of the side effects of this medicine may worsen the symptoms of other conditions. For this reason, it is important that you discuss with your doctor any of the following conditions, which may worsen during treatment with this medicine:
If you have any of these conditions, please consult your doctor as it may be necessary to adjust your dose or keep you under observation for a time.
Because in very rare cases, a dangerously low number of a type of white blood cell necessary to fight infections in the blood has been observed in patients treated with this medicine, your doctor may check your white blood cell count.
Even if you have previously tolerated paliperidone oral or risperidone, rare allergic reactions may occur after receiving paliperidone injections. Seek immediate medical help if you experience a skin rash, swelling of the throat, itching, or breathing problems, as these may be signs of a severe allergic reaction.
This medicine may cause you to gain weight. Significant weight gain can negatively affect your health. Your doctor will regularly monitor your weight.
In patients treated with this medicine, diabetes mellitus or worsening of pre-existing diabetes mellitus has been observed. Your doctor should check for signs of increased blood sugar. In patients with pre-existing diabetes mellitus, blood sugar should be regularly monitored.
Since this medicine may mask the normal response of the body to the ingestion of toxic substances or other conditions, there is a possibility that it may mask the symptoms of other conditions.
During eye surgery for cataracts, the pupil (the black circle in the middle of the eye) may not dilate as needed. Additionally, the iris (the colored part of the eye) may become flaccid during surgery and this may cause eye damage. If you are planning to have eye surgery, be sure to inform your ophthalmologist that you are using this medicine.
Children and adolescents
Do not use this medicine in patients under 18 years.
Other medicines and BACEQ
Inform your doctor if you are using, have used recently, or may need to use any other medicine.
The use of this medicine with carbamazepine (an antiepileptic and mood stabilizer) may require a change in your dose of this medicine.
Since this medicine acts mainly on the brain, interaction with other medicines that also act on it may cause an exaggeration of side effects, such as drowsiness or other effects on the brain, such as other psychiatric medicines, opioids, antihistamines, and sleep medicines.
Since this medicine may lower blood pressure, you should be careful if you use this medicine with other medicines that also lower blood pressure.
This medicine may reduce the effect of medicines for Parkinson's disease and restless leg syndrome (e.g., levodopa).
This medicine may cause an abnormality in the electrocardiogram (ECG) that shows that a certain part of the heart takes a longer time to travel an impulse (known as "prolongation of the QT interval"). Other medicines that have this effect include some medicines used to treat heart rhythm or to treat infections, as well as other antipsychotics.
If you are prone to seizures, this medicine may increase your chances of experiencing them. Other medicines that have this effect include some medicines used to treat depression or to treat infections, as well as other antipsychotics.
BACEQ should be used with caution with medicines that increase the activity of the central nervous system (psycho-stimulants such as methylphenidate).
Use of BACEQ with alcohol
Alcohol should be avoided.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medicine. Do not use this medicine during pregnancy unless you have discussed it with your doctor. The following symptoms may occur in newborn babies of mothers who have been treated with paliperidone in the last three months of pregnancy (last three months of your pregnancy): tremor, rigidity, and/or muscle weakness, drowsiness, agitation, breathing problems, and difficulty feeding. If your baby develops any of these symptoms, contact your doctor.
This medicine may pass from mother to baby through breast milk and may harm the baby. Therefore, do not breastfeed while using this medicine.
Driving and operating machinery
During treatment with this medicine, dizziness, extreme fatigue, and vision problems (see section 4) may occur. This should be taken into account when requiring maximum attention, for example, when driving or operating machinery.
BACEQ contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose; this is essentially "sodium-free".
Your doctor or another healthcare professional will administer this medication. Your doctor will inform you when the next injection should be administered. It is essential that you do not miss any scheduled doses. If you cannot attend your appointment with the doctor, please make sure to call them immediately to schedule another appointment as soon as possible.
You will receive the first injection (150 mg) and the second injection (100 mg) of this medication in the upper arm approximately one week apart. From then on, you will receive an injection (between 25 mg and 150 mg) in the upper arm or buttocks once a month.
If your doctor is changing you from risperidone long-acting injectable to this medication, you will receive the first injection of this medication (between 25 mg and 150 mg) in the upper arm or buttocks at the next scheduled injection. From then on, you will receive an injection (between 25 mg and 150 mg) in the upper arm or buttocks once a month.
Your doctor may increase or decrease the amount of medication you receive at the time of the scheduled monthly injection based on your symptoms.
Patients with kidney problems
Your doctor may adjust the dose of this medication according to your renal function. If you have mild kidney problems, your doctor may give you a lower dose. You should not use this medication if you have moderate or severe kidney problems.
Patients of advanced age
Your doctor may reduce the dose of this medication if your kidney function is decreased.
If you use more BACEQ than you should
You will receive this medication under medical supervision; it is therefore unlikely that you will receive an excessive dose.
Patients who have received an excessive amount of paliperidone may experience the following symptoms: drowsiness or sedation, rapid heart rate, low blood pressure, electrocardiogram abnormalities (heart tracing), or slow or abnormal movements of the face, body, arms, or legs.
If you interrupt treatment withBACEQ
If you stop receiving your injections, the effects of the medication will be lost. Do not stop using this medication unless your doctor tells you to, as your symptoms may return.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Inform your doctor immediately if:
The following side effects may occur:
Very common side effects: can affect more than 1 in 10 patients
Common side effects: can affect up to 1 in 10 patients
Rare side effects: can affect up to 1 in 100 patients
Rare side effects: can affect up to 1 in 1,000 patients
Unknown frequency: cannot be estimated from available data
Reporting of side effects
If you experience any type of side effect, consult your doctor or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System of Pharmacovigilance of Medicines for Human Use:https://www.notificaRAM.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the pre-filled syringe and on the box after “CAD or EXP”. The expiration date is the last day of the month indicated.
This medication does not require any special storage conditions.
Medications should not be disposed of through drains or in the trash. Dispose of the containers and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.
Composition of BACEQ
The active ingredient is paliperidone
Each BACEQ 25 mg pre-filled syringe contains 39 mg of palmitate of paliperidone in 0.25 ml.
Each BACEQ 50 mg pre-filled syringe contains 78 mg of palmitate of paliperidone in 0.5 ml.
Each BACEQ 75 mg pre-filled syringe contains 117 mg of palmitate of paliperidone in 0.75 ml.
Each BACEQ 100 mg pre-filled syringe contains 156 mg of palmitate of paliperidone in 1 ml.
Each BACEQ 150 mg pre-filled syringe contains 234 mg of palmitate of paliperidone in 1.5 ml
Starting treatment package:
Each BACEQ 100 mg pre-filled syringe contains 156 mg of palmitate of paliperidone in 1 ml.
Each BACEQ 150 mg pre-filled syringe contains 234 mg of palmitate of paliperidone in 1.5 ml
The other components are:
polysorbate 20
macrogol 4000
monohydrate citric acid
disodium phosphate
dihydrogen phosphate of sodium monohydrate
sodium hydroxide (for pH adjustment)
water for injection
Appearance of the product and contents of the package
BACEQ is a white to off-white prolonged-release injectable suspension, which comes in a pre-filled syringe (prolonged-release injectable)
Each package contains 1 pre-filled syringe and 2 needles.
Starting treatment package:
Each package contains 1 BACEQ 150 mg package and 1 BACEQ 100 mg package.
Only some package sizes may be marketed.
Marketing authorization holder and manufacturer responsible
Marketing authorization holder
Teva Pharma, S.L.U.
C/ Anabel Segura, 11, Edificio Albatros B, 1st floor,
Alcobendas, 28108, Madrid (Spain)
Manufacturer responsible:
Actavis Group PTC ehf.
Dalsharun 1
IS-220 Hafnarfjordur
Iceland
For more information about this medicine, please contact the local representative of the marketing authorization holder:
Laboratorios Farmacéuticos ROVI, S.A.
Julián Camarillo, 35
28037 – Madrid – Spain
This medicine is authorized in the Member States of the European Economic Area with the following names:
|
Last review date of this leaflet:February 2024
More detailed information about this medicine is available on the website of theSpanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es
This information is intended only for doctors or healthcare professionals and should be read together with the complete prescribing information (Summary of Product Characteristics).
The injectable suspension is for single use. It should be visually inspected to detect any foreign particles before administration. Do not use the product if the syringe is not visually free of foreign particles.
The package contains a pre-filled syringe and two safety needles (one 22 gauge 1½ inch [38.1 mm x 0.72 mm] needle with a blue shaft and one 23 gauge 1 inch [25.4 mm x 0.64 mm] needle with a grey shaft) for intramuscular injection. BACEQ is also available in a treatment initiation pack containing two pre-filled syringes (150 mg + 100 mg) and two additional safety needles.
The first dose of BACEQ (150 mg) is administered on Day 1 in the deltoid muscle using the deltoid muscle injection needle. The second dose of BACEQ (100 mg) is administered also in the deltoid muscle one week later (Day 8) using the deltoid muscle injection needle.
If the patient is switched from risperidone prolonged-release injectable to BACEQ, the first BACEQ injection (dose range 25 mg to 150 mg) can be administered in the deltoid muscle or gluteus muscle using the appropriate needle for the injection site at the time of the next scheduled injection.
Subsequent monthly maintenance injections can be administered in both the deltoid muscle and gluteus muscle using the appropriate needle for the injection site.
For deltoid muscle injection, if the patient weighs <90>23kg, use the 23 gauge 1 inch [25.4 mm x 0.64 mm] needle (needle with a blue shaft); if the patient weighs?90 kg, use the 22 gauge 1½ inch [38.1 mm x 0.72 mm] needle (needle with a grey shaft).
For gluteus muscle injection, use the 22 gauge 1½ inch [38.1 mm x 0.72 mm] needle (needle with a grey shaft).
8a
8b
8c
The disposal of unused medication and all materials that have come into contact with it will be carried out in accordance with local regulations.
The average price of Baceq 75 mg suspension inyectable de liberacion prolongada efg in July, 2025 is around 152.41 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.